Drilldown: Medicines
Use the filters below to narrow your results.
generic: (Click arrow to add another value)
brand:
classes:
mechanism:
None (1) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)
uses:
starting dose:
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
70 mg SC monthly; may increase to 140 mg monthly (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) ·
Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours (1)
preparations:
120 mg/mL prefilled syringe or autoinjector (1) ·
225 mg/1.5 mL prefilled syringe or autoinjector (1) ·
70 mg/mL or 140 mg/mL prefilled autoinjector (1) ·
Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) (1)
fda max:
routes: (Click arrow to add another value)
onset:
duration:
bioavailability:
pregnancy:
Showing below up to 4 results in range #1 to #4.